Abstract
Somatostatin receptor imaging (SRI) was carried out as part of the initial staging of 26 patients with histologically proven Hodgkin's (3) and non-Hodgkin's (23) lymphoma, and in the assessment of the first treatment's efficacy in seven of these patients. Static acquisitions over the whole body were performed 4 and 24 h after intravenous administration of 150 MBq of indium-111 pentetreotide. SRI data were compared with the results of conventional methods (clinical data, abdominal and thoracic computed tomography, bone marrow biopsy). Only 50 of the 86 (58%) confirmed extra-medullary tumour sites were detected by SRI. Twelve previously unknown localizations were visualized in seven patients. The Ann Arbor clinical stage was modified in only one of them. When tumoral tracer uptake was present, a tumour uptake index (TUI) was calculated using two regions of interest (one over the tumoral hot spot and one over the shoulder) on 24-h planar images. The patients were classified into three groups: high tumour uptake (TUI>2.5 in all tumour sites, group A, six patients), low tumour uptake (1.5<TUI<2.5 in all tumour sites, group B, 18 patients), and no tumour uptake (group C, two patients). The sensitivity of SRI detection was higher in group A (90%) than in group B (52%) (P<0.001). Six weeks after the fourth chemotherapy cycle, conventional methods and SRI were concordant in five of seven investigated cases (four complete remissions and one residual active thoracic mass showing tracer uptake), and discordant in two. SRI demonstrated residual tumoral tracer uptake in these two patients, who had previously been considered to be in complete remission. In conclusion, SRI does not seem to be reliable for the initial staging of lymphomas because of the highly variable and usually low tumoral tracer uptake. It may be more useful in the diagnosis of residual masses after treatment. However, further studies are needed to assess its specificity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bhathena SJ, Louie J, Schechter GP, Redman RS, Wahl L, Recant L. Identification of human mononuclear leukocytes bearing receptors for somatostatin and glucagon.Diabetes 1981; 30: 127–131.
Hiruma K, Koike T, Nakamura H, Sumida T, Maeda T, Tomioka H, Yoshida S, Fujita T. Somatostatin receptors on human lymphocytes and leukaemia cells.Immunology 1990; 71: 480–485.
Reubi JC, Horisberger U, Waser B, Gebbers JO, Laissue J. Preferential location of somatostatin receptors in germinal centers of human gut lymphoid tissue.Gastroenterology 1992; 103: 1207–1214.
Scicchitano R, Dazin B, Bienenstock J, Payan DG, Stanisz AM. Distribution of somatostatin receptors on murine spleen and Peyer's patch T and B lymphocytes.Brain Behav Immunol 1987; 1: 173–184.
Nakamura H, Koike T, Hiruma K, Sato T, Tomioka H, Yoshida S. Identification of lymphoid cell lines bearing receptors for somatostatin.Immunology 1987; 62: 655–658.
Hiruma K, Koike T, Nakamura H, Sumida T, Maeda T, Tomioka H, Yoshida S, Fujita T. Somatostatin receptors on human lymphocytes and leukaemia cells.Immunology 1990; 71: 480–485.
Sreedharan P, Kodama KT, Peterson KE, Goetzl EJF. Distinct subsets of somatostatin receptors on cultured human lymphocytes.J Biol Chem 1989; 264: 949–952.
Reubi JC, Waser B, van Hagen M, Lamberts SWJ, Krenning EP, Gebbers JO, Laissue JA. In vitro and in vivo detection of somatostatin receptors in human malignant lymphomas.Int J Cancer 1990; 50: 895–900.
VanHagen PM, Krenning EP, Reubi JC, Mulder AH, Bakker WH, Oei HY, Löwenberg B, Lambert SWJ. Somatostatin analogue scintigraphy of malignant lymphomas.Br J Haematol 1993; 83: 75–79.
Moormeier JA, Williams SF, Colomb HM. The staging of Hodgkin's disease.Hematol Oncol Clin North Am 1989; 3: 237–251.
Coiffier B, Shipp MA, Cabanillas F, Crowther D, Armitage JO, Canellos GP. Report of the first workshop on prognostic factors in large-cell lymphomas.Ann Oncol 1991; 2: 213–217.
Bares R, Galonska P, Dempke W, Handt S, Büll U, Osieka R. Somatostatin receptor scintigraphy in malignant lymphoma: first results and comparison with glucose metabolism measured by positron-emission tomography.Horm Metab Res Suppl 1992; 27: 56–58.
Ivancevic V, Nauck C, Wörmann B, Sandrock D, Hiddemann W, Munz DL, Emrich D. Somatostatin receptor scintigraphy in Hodgkin (LH) and non-Hodgkin lymphomas (NHL) [Abstract].J Nucl Med 1994; 35: 132.
Lipp RW, Silly H, Bauer F, Jäger G, Passath A, Dobnig H, Leh G, Krejs GJ. Demonstration of lymphomas using a radiolabelled somatostatin analogue (Octreoscan) [Abstract].Eur J Nucl Med 1993; 20: 845.
Stoffel M, Jamar F, Martiat P, Leners N, Beckers C, Ferrant A, Pauwels S. Somatostatin receptor imaging in lymphomas [Abstract].J Nucl Med 1994; 35: 131.
Van den Anker-Lugtenburg PJ, Krenning EP, Oei HY, Gerrits CJH, Vanhagen PM, Reubi JC, Lamberts SWJ, Löwenberg B. The role of somatostatin receptor scintigraphy (SRS) in the initial staging of malignant lymphoma [Abstract].J Nucl Med 1994; 35: 132.
Epelbaum J.Récepteurs hypophysaires et mécanismes de transduction. International Pituitary Congress. Marina Del Rey, USA, 1993.
Eden PA, Taylor JE. Somatostatin receptor subtype gene expression in human and rodent tumours.Life Sci 1994; 53: 85–90.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sarda, L., Duet, M., Zini, J.M. et al. Indium-111 pentetreotide scintigraphy in malignant lymphomas. Eur J Nucl Med 22, 1105–1109 (1995). https://doi.org/10.1007/BF00800590
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00800590